Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate Suppositories for Anal HSIL
NCT05555862Phase 2Active, not recruiting
- Sponsor
- Frantz Viral Therapeutics
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anal squamous intraepithelial lesion (ASIL) comparing Artesunate with Placebo (2 arms). Primary endpoint: Number of subjects with complete and partial response by week 18. Started Feb 2023; status: active, not recruiting.
02
Drugs
artesunate
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT05555862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555862.